Erytech Pharma SA (ERYP) Gets a Buy Rating from Cowen & Co.


In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Erytech Pharma SA (ERYP). The company’s shares closed on Monday at $6.66.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 2.8% and a 42.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The the analyst consensus on Erytech Pharma SA is currently a Moderate Buy rating.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.89 and a one-year low of $5.45. Currently, Erytech Pharma SA has an average volume of 2,197.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts